214 related articles for article (PubMed ID: 34011212)
21. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.
Chiricozzi A; Zangrilli A; Bavetta M; Bianchi L; Chimenti S; Saraceno R
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):304-311. PubMed ID: 27324646
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
[TBL] [Abstract][Full Text] [Related]
23. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
Mastorino L; Susca S; Cariti C; Sliquini N; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Ribero S; Quaglino P
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1848-1853. PubMed ID: 37113043
[TBL] [Abstract][Full Text] [Related]
25. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.
Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL
Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
[TBL] [Abstract][Full Text] [Related]
27. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
28. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre.
Gallo G; Rostagno E; Siliquini N; Stroppiana E; Verrone A; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Australas J Dermatol; 2021 Aug; 62(3):e431-e432. PubMed ID: 34042171
[No Abstract] [Full Text] [Related]
30. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV
Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652
[TBL] [Abstract][Full Text] [Related]
32. Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.
Bellinato F; Gisondi P; Mason E; Ricci P; Maurelli M; Girolomoni G
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1303-1311. PubMed ID: 35476248
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
[TBL] [Abstract][Full Text] [Related]
34. ABP 501 for the treatment of rheumatoid arthritis.
Pelechas E; Voulgari PV; Drosos AA
Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
[TBL] [Abstract][Full Text] [Related]
35. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
36. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
[TBL] [Abstract][Full Text] [Related]
37. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
38. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL; Jørgensen KK; Sexton J; Olsen IC; Bolstad N; Haavardsholm EA; Lundin KEA; Tveit KS; Lorentzen M; Berset IP; Fevang BTS; Kalstad S; Ryggen K; Warren DJ; Klaasen RA; Asak Ø; Baigh S; Blomgren IM; Brenna Ø; Bruun TJ; Dvergsnes K; Frigstad SO; Hansen IM; Hatten ISH; Huppertz-Hauss G; Henriksen M; Hoie SS; Krogh J; Midtgard IP; Mielnik P; Moum B; Noraberg G; Poyan A; Prestegård U; Rashid HU; Strand EK; Skjetne K; Seeberg KA; Torp R; Ystrøm CM; Vold C; Zettel CC; Waksvik K; Gulbrandsen B; Hagfors J; Mørk C; Jahnsen J; Kvien TK
J Intern Med; 2019 Jun; 285(6):653-669. PubMed ID: 30762274
[TBL] [Abstract][Full Text] [Related]
40. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
